VRK2 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of Vaccinia-Related Kinase 2 (VRK2), a serine/threonine protein kinase that plays a pivotal role in various cellular processes, including signal transduction, cell cycle regulation, and stress response pathways. VRK2 is part of the VRK family of kinases, which are involved in the regulation of several key cellular functions, such as DNA damage response, transcriptional regulation, and apoptosis. VRK2 is particularly notable for its role in modulating signaling pathways like the MAPK (mitogen-activated protein kinase) pathway, where it interacts with scaffold proteins and regulates the activation of downstream effectors, such as ERK (extracellular signal-regulated kinase). By inhibiting VRK2, researchers can disrupt these signaling pathways, providing a powerful tool to study the specific contributions of VRK2 to cellular signaling networks and its broader impact on cellular function.
In research settings, VRK2 inhibitors are valuable for exploring the intricate mechanisms by which VRK2 influences cellular behavior and maintains cellular homeostasis. By blocking VRK2 activity, scientists can investigate how the inhibition affects the MAPK pathway and other associated signaling cascades, particularly focusing on the downstream effects on gene expression, cell proliferation, and stress responses. This inhibition allows researchers to examine the role of VRK2 in cell cycle progression, apoptosis, and the cellular response to DNA damage. Additionally, VRK2 inhibitors provide insights into the interactions between VRK2 and other signaling molecules, such as scaffold proteins and transcription factors, revealing the complex networks that govern cellular signaling and decision-making processes. Through these studies, the use of VRK2 inhibitors enhances our understanding of the molecular mechanisms underlying signal transduction, the regulation of cell cycle and stress responses, and the broader implications of VRK2 activity in maintaining cellular integrity and function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which is part of the stress-activated protein kinase pathway influenced by VRK2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, another kinase that can be regulated by VRK2 activity. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Inhibits cyclin-dependent kinases, which could be involved in cell cycle regulation with VRK2. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
Inhibits Akt, which may interact with pathways where VRK2 is present. | ||||||
ATM Kinase Inhibitor | 587871-26-9 | sc-202963 | 2 mg | $110.00 | 28 | |
Inhibits ATM kinase, which is involved in DNA damage response, potentially linked with VRK2. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
Inhibits ATR, which is part of the response to DNA damage and may be influenced by VRK2. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
Inhibits CHK1, a kinase involved in DNA damage checkpoints potentially regulated by VRK2. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Inhibits Aurora B kinase, possibly affecting cell division processes regulated by VRK2. | ||||||
2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one | 955365-80-7 | sc-483196 | 5 mg | $340.00 | 1 | |
Inhibits Wee1, a kinase that regulates the cell cycle and may intersect with VRK2 pathways. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
Inhibits Polo-like kinase 1, which has roles in cell cycle potentially affected by VRK2. | ||||||